Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.
Crizotinib for First Line Treatment of ALK or ROS1 Rearrangements [720p]
